Evaluation of Therapeutic Interventions for Vaccinia Virus Keratitis
Evaluation of Therapeutic Interventions for Vaccinia Virus Keratitis
复制标题
DOI：
10.1093/infdis/jiq103
复制
发表时间：
2011-03-01
影响因子：
6.4
通讯作者：
Kodihalli, Shantha
中科院分区：
文献类型：
--
作者：
Altmann, Sharon;Brandt, Curtis R.;Kodihalli, Shantha
方法.用10（5）个噬斑形成单位的Dryvax牛痘病毒株感染兔眼，并使用改良的MacDonald-Shadduck评分系统每日评分，持续28天。在角膜炎发作后，用白蛋白、VIG、醋酸泼尼松龙、曲氟尿苷或其组合治疗动物10天。采用空斑法和酶联免疫吸附法分别测定眼部病毒滴度和牛痘特异性抗体滴度。静脉注射VIG治疗既不加重也不改善VACVK。局部醋酸泼尼松龙干扰病毒清除，泼尼松龙治疗组眼部疾病反弹。最有效的治疗方法是外用曲氟尿苷。我们得出结论：（1）VIG对孤立性角膜炎的治疗没有负面影响，（2）局部皮质类固醇不应用于治疗VACVK，（3）局部曲氟尿苷治疗，伴或不伴静脉注射VIG，是治疗VACVK的首选治疗方案。
Methods. Rabbit eyes were infected with 10(5) plaque-forming units of the Dryvax strain of vaccinia virus and scored daily for 28 days using a modified MacDonald-Shadduck scoring system. Animals were treated for 10 days after the onset of keratitis with albumin, VIG, prednisolone acetate, trifluridine, or combinations thereof. Ocular viral titers and vaccinia-specific antibody titers were determined by plaque assay and enzyme-linked immunosorbent assay, respectively.Results. Treatment with intravenous VIG neither exacerbated nor ameliorated VACVK. Topical prednisolone acetate interfered with viral clearance, and ocular disease rebounded in prednisolone-treated groups. The most effective treatment was topical trifluridine alone.Conclusions. We conclude that (1) VIG did not negatively affect the treatment of isolated keratitis, (2) topical corticosteroids should not be used for treating VACVK, and (3) treatment with topical trifluridine, with or without intravenous VIG, is the preferred therapeutic regimen for treating VACVK.